Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.61 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.61 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance. They highlighted the importance of their clinical programs but did not provide specific guidance.
Management did not provide specific insights on revenue expectations.
The company remains focused on its ongoing clinical trials.
The earnings report indicates that Protagonist Therapeutics is still in a challenging phase, as evidenced by the missed EPS. The stock fell by 5.77% following the announcement, reflecting investor concerns over the lack of revenue details and future guidance. The focus remains on their clinical trials, but uncertainty may weigh on investor sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CONSOLIDATED EDISON
Nov 4, 2019